The invention refers to new compounds that inhibit the reprocessing of 500 enzymes (RET) during blood transfusion,A pharmaceutical ingredients containing these substances, their preparation procedures, and standardized procedures for sensitivity, either alone or in combination, for treatment, Treatment of gastrointestinal motility and / or secretory and / or abdominal diseases and / or disorders related to gastrointestinal dysfunction and / or disorders related to gastrointestinal dysfunction, or where modulation of gastrointestinal activity can bring therapeutic benefits, including, but not limited to, all classifications of irritable bowel syndrome (i) Including major diarrhea, major constipation or alternate feces, functional swelling, functional constipation, functional diarrhea,unspecified functional intestinal disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, spinal cancer Thyroid, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancers, head and neck cancer, gliomas, neuroblastomas,Von hipperl Lindau syndrome and renal tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, esophageal cancer and gastrointestinal colitis, cholangiocarcinoma, adenomas, and any increased quinasa RET activity malignancies.Esta invención se refiere a nuevos compuestos que son inhibidores de la quinasa de reorganizado durante la transfección (RET), a composiciones farmacéuticas que los contienen, a procedimientos para su preparación y a su uso en terapia, solos o en combinación, para la normalización de la sensibilidad, motilidad y/o secreción gastrointestinal y/o trastornos o enferm
